Canadian Bio Med Systems gains license for Ocular Thera drugs
Canadian Bio Med Systems has signed a preliminary agreement for the licensing rights to two new ophthalmic drugs from California, USA-based Ocular Therapeutics for the treatment of wet age related macular degeneration.
The first is a protein called LD22-4, which targets cell migration. It has a mode of action that is distinct from other drugs that are on the market, or that are in development by other biotechnology or pharmaceutical companies, the firm says.
Ocular Therapeutics also owns the worldwide exclusive license to a patent-pending non-surgical treatment of glaucoma. The agent lowers intraocular pressure and thus may slow the damage to the retinal cells. The product needs to be used only once or twice per year by the patient.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze